A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MI / more intensive

[Related PubMed/MEDLINE]
Total Number of Papers: 14
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MI  (>> Co-occurring Abbreviation)
Long Form:   more intensive
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts. CsA, DSAs, LI
2018 De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. DSAs, LI, MFI
2018 Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. LI, LTE
2018 Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT. DSAs, LI, MFI
2016 Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. CI, eGFR, HRs, LI
2013 Insulin regimens and clinical outcomes in a type 1 diabetes cohort: the SEARCH for Diabetes in Youth study. LI
2013 Long-term exposure to belatacept in recipients of extended criteria donor kidneys. CsA, LI, LTE, PTLD
2012 Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. BPAR, LI
2012 Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. cGFR, CKD, ECD, LI, PTLD
10  2011 Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). CsA, LI, NODAT
11  2011 Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. LI, PD
12  2010 A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). LI, mGFR
13  2010 An integrated safety profile analysis of belatacept in kidney transplant recipients. CNS, LI, PTLD
14  2010 Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. BENEFIT, CsA, EBV, LI, PTLD